“Efficacy and Safety of Dapagliflozin as Adjunct Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea” (2026) Academia Journal of Medicine, 9(2), pp. 201–205. doi:10.48165/ajm.2026.9.02.34.